KA
REGN icon

Kintegral Advisory’s Regeneron Pharmaceuticals REGN Stock Holding History

Kintegral Advisory’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$696K Hold
1,116
– – 0.06% 200
2026
Q1 		$862K Sell
1,116
-50
-4% -$38.3K 0.08% 180
2025
Q4 		$900K Sell
1,166
-32
-3% -$21.7K 0.08% 182
2025
Q3 		$674K Sell
1,198
-5
-0.4% -$2.83K 0.06% 205
2025
Q2 		$632K Sell
1,203
-3
-0.2% -$1.67K 0.06% 208
2025
Q1 		$765K Sell
1,206
-4
-0.3% -$2.75K 0.08% 192
2024
Q4 		$862K Sell
1,210
-57
-4% -$47.8K 0.08% 188
2024
Q3 		$1.33M Sell
1,267
-16
-1% -$17.8K 0.12% 156
2024
Q2 		$1.35M Buy
1,283
+601
+88% +$583K 0.13% 155
2024
Q1 		$656K Sell
682
-2
-0.3% -$1.9K 0.07% 196
2023
Q4 		$601K Sell
684
-4
-0.6% -$3.29K 0.07% 201
2023
Q3 		$566K Hold
688
– – 0.07% 196
2023
Q2 		$494K Hold
688
– – 0.06% 209
2023
Q1 		$565K Sell
688
-37
-5% -$27.9K 0.07% 195
2022
Q4 		$523K Sell
725
-239
-25% -$176K 0.07% 204
2022
Q3 		$664K Hold
964
– – 0.09% 178
2022
Q2 		$570K Buy
964
+21
+2% +$13.7K 0.07% 203
2022
Q1 		$659K Buy
943
+21
+2% +$13.3K 0.07% 201
2021
Q4 		$582K Hold
922
– – 0.06% 222
2021
Q3 		$558K Hold
922
– – 0.07% 220
2021
Q2 		$515K Hold
922
– – 0.06% 225
2021
Q1 		$436K Hold
922
– – 0.06% 238
2020
Q4 		$445K Hold
922
– – 0.06% 230
2020
Q3 		$516K Sell
922
-30
-3% -$18.2K 0.08% 196
2020
Q2 		$594K Hold
952
– – 0.1% 181
2020
Q1 		$465K Buy
952
+107
+13% +$44.1K 0.09% 189
2019
Q4 		$317K Hold
845
– – 0.06% 251
2019
Q3 		$234K Hold
845
– – 0.05% 264
2019
Q2 		$264K Hold
845
– – 0.05% 264
2019
Q1 		$347K Buy
845
+37
+5% +$15.2K 0.07% 232
2018
Q4 		$302K Buy
+808
New +$296K 0.09% 185

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Kintegral Advisory's REGN Position: Q2 2026 in Review

Kintegral Advisory held its Regeneron Pharmaceuticals (REGN) position steady in Q2 2026 at 1,116 shares worth $696K. The position accounts for 0.06% of the portfolio, ranked #200.

Kintegral Advisory first reported a position in REGN in Q4 2018 and has held it in 31 quarters since. The position peaked at $1.35M in Q2 2024. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Kintegral Advisory held 1,116 shares of Regeneron Pharmaceuticals worth $696K as of Q2 2026.
  • Kintegral Advisory left its Regeneron Pharmaceuticals share count unchanged in Q2 2026.
  • Regeneron Pharmaceuticals made up 0.06% of Kintegral Advisory's portfolio in Q2 2026, its #200 holding.
  • Kintegral Advisory first reported a position in Regeneron Pharmaceuticals in Q4 2018 and has held it in 31 quarters since.
  • Kintegral Advisory's Regeneron Pharmaceuticals position peaked at $1.35M in Q2 2024.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Kintegral Advisory's 13F filing for Q2 2026, filed 29 Jul 2026.